IL17A and myeloid sarcoma: IL-17RA has been found to be highly expressed in the CA1 region of the hippocampus, and the exposure to IL-17A has been shown to disrupt hippocampal long-term potentiation in a dose-dependent manner through the activation of its receptor and p38 MAPK, suggesting a potential involvement of the IL-17 axis in IL-17A expression has been shown to impair hippocampal long-term potentiation MS-associated cognitive impairment (Di Filippo et al., 2021).